Aridis Pharmaceuticals, Inc.

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:27:27 28/06/2024 am IST			5-day change	1st Jan Change
0.061 ^USD	-3.17%		-15.75%	-12.98%

24/06	Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	CI
2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Shenzhen Ruidi Biopharmaceutical Co., Ltd. announced that it has received $2.357647 million in funding from Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Aridis Pharmaceuticals, Inc.

January 05, 2019

On January 5, 2019, Shenzhen Ruidi Biopharmaceutical Co., Ltd. closed the transaction.

Latest news about Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	25/06	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	04/11	CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer	10/23/10	CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index	21/23/21	CI
Sector Update: Health Care Stocks Steady Premarket Tuesday	18/23/18	MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	18/23/18	MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index	18/23/18	CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	18/23/18	MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	18/23/18	CI
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301	12/23/12	DJ
Aridis Pharmaceuticals Gets FDA Product Designation for AR-301	12/23/12	DJ
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	12/23/12	CI
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	20/23/20	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Sector Update: Health Care Stocks Advancing Late Wednesday	01/23/01	MT
Sector Update: Health Care	01/23/01	MT
Top Midday Gainers	31/23/31	MT
Aridis Pharma Shares Double After FDA Clearance to Start AR-301 Pneumonia Study	31/23/31	DJ
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	31/23/31	CI
Aridis Pharmaceuticals Files $3 Million Mixed Securities Registration Statement	23/23/23	MT

Chart Aridis Pharmaceuticals, Inc.

Duration

Period

More charts

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Companyâs clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ARIDIS PHARMACEUTICALS, INC.	-12.98%	30.9L
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.65%	12TCr
ARGENX SE	+21.22%	2.66TCr
BIONTECH SE	-23.84%	1.99TCr
GENMAB A/S	-17.47%	1.63TCr
WUXI APPTEC CO., LTD.	-45.95%	1.55TCr
BEIGENE, LTD.	-19.28%	1.55TCr
SAREPTA THERAPEUTICS, INC.	+63.81%	1.48TCr
NEUROCRINE BIOSCIENCES, INC.	+1.94%	1.37TCr

Bio Therapeutic Drugs

Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Shenzhen Ruidi Biopharmaceutical Co., Ltd. announced that it has received $2.357647 million in funding from Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Aridis Pharmaceuticals, Inc.

Latest news about Aridis Pharmaceuticals, Inc.

Chart Aridis Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs